The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for a cholesterol ester transfer protein inhibitor, after more than a decade of failed attempts by rival developers.
Media partner
PHARMA REGULATION · CARDIOVASCULAR APPROVAL · SEPTEMBER 26, 2026 · EUROPE
After more than a decade in which most major attempts to bring a cholesterol ester transfer protein (CETP) inhibitor to patients ended in late-stage failure, the European Commission on September 21, 2026 approved obicetrapib — as Ubeslo (monotherapy) and Evlarco (a fixed-dose combination with ezetimibe) — for adults with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH), or mixed dyslipidaemia, according to a press release issued jointly by Menarini Group, the Florence-based international pharmaceutical group, and NewAmsterdam Pharma, its development partner. The companies describe it as a first-in-class approval and the first regulatory approval of obicetrapib worldwide.
The commercial and scientific weight of that distinction is real but requires context. Pfizer’s torcetrapib, Roche’s dalcetrapib, and Eli Lilly’s evacetrapib each failed in Phase 3 trials — torcetrapib on cardiovascular mortality, dalcetrapib on efficacy, evacetrapib on a composite cardiovascular endpoint — leaving the CETP mechanism widely regarded as a dead end. NewAmsterdam’s case, accepted by the European Medicines Agency (EMA, the EU’s centralised drug regulator) and converted into a Commission decision, rests on the argument that obicetrapib’s molecular profile differs sufficiently from its predecessors to produce a distinct benefit-risk balance. The companies say the approval is supported by the Phase 3 BROADWAY, BROOKLYN and TANDEM trials; the EMA’s full assessment report had not been published in the sources available at the time of writing.
A class rehabilitated — with conditions
Under the licence agreement between the two companies, NewAmsterdam is eligible for up to an additional €833 million in clinical, regulatory and commercial milestone payments, plus tiered double-digit royalties on net sales, according to the companies’ announcement. No peak-sales estimate for obicetrapib has been independently corroborated in the materials reviewed for this article; given the class’s history, any such projection carries substantial uncertainty.
The reimbursement gap that approval does not close
European Commission marketing authorisation is the beginning of a commercial pathway, not its conclusion. In Spain, the average time between EMA authorisation and national funding reached 537 days according to the Waiting to Access Innovative Therapies (WAIT) 2025 report, released by Farmaindustria in May 2026 — nearly triple the 180-day maximum set by EU directive. Only 8% of medicines received funding within that 180-day window, per the same report. Germany, France, Italy, and Spain each operate distinct health-technology assessment (HTA) frameworks, and obicetrapib will face separate pricing and reimbursement negotiations in each. The WAIT 2025 data also showed that more than half of newly funded medicines in Spain carried indication restrictions relative to the EMA label — a pattern that could limit obicetrapib’s accessible patient population even after national funding is secured.
The named incumbent products whose market position obicetrapib most directly challenges are the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors — evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron) — which currently occupy the primary non-statin LDL-lowering slot in European formularies. Neither Amgen nor Sanofi has commented publicly on the obicetrapib approval in the sources available. Inclisiran (Leqvio, Novartis), a small interfering RNA agent with a twice-yearly dosing schedule, represents a third established competitor in the same patient population. How payers weigh obicetrapib’s mechanism and tolerability profile against these already-reimbursed alternatives will determine whether the approval generates meaningful volume or remains a niche option for patients who have exhausted prior lines.
A structural friction point deserves direct statement. The CETP class’s prior failures were not purely commercial — they generated safety signals (torcetrapib raised blood pressure and increased cardiovascular events) and efficacy gaps that shaped payer and physician scepticism at an institutional level. Formulary committees in markets with long institutional memory of those trials may apply additional scrutiny to obicetrapib’s dossier, independent of the Commission’s positive opinion.
On the question of access beyond Europe: filings with ANVISA, Brazil’s health surveillance agency; COFEPRIS, Mexico’s Federal Commission for Protection against Sanitary Risks; or ANMAT, Argentina’s national medicines regulator, have not been announced in the available record. No Latin American regulatory pathway has been publicly disclosed by either company at this stage.
What to Watch
- Publication of the EMA’s full Committee for Medicinal Products for Human Use (CHMP) assessment report, which will clarify the clinical data package and any label restrictions relative to the approved indication
- National HTA submissions and pricing decisions in Germany (where the Joint Federal Committee, known as the G-BA, conducts early benefit assessments), France (Haute Autorité de Santé), and Spain (the Interministerial Pricing Commission), each of which will set the effective access timeline independently of the Commission’s approval
- Any PCSK9 inhibitor manufacturer response — label expansions, price adjustments, or outcomes-based contracting offers — that could pre-empt obicetrapib’s formulary positioning before national reimbursement decisions are finalised
The HealthSignals Brief
The signals that move health markets in Latin America and the US — every two weeks, in one PDF.
Free. Unsubscribe anytime.
The deeper signal from this approval may be less about obicetrapib specifically and more about what it implies for the broader pipeline of cardiovascular mechanisms that were abandoned after the CETP failures of the 2010s. If national HTA bodies in Germany and France grant obicetrapib a meaningful added-benefit rating — the threshold that determines whether a drug commands a premium price or defaults to a reference price — it would constitute the first independent regulatory validation of the CETP mechanism’s clinical utility, potentially reopening commercial interest in related targets. That outcome remains speculative; the HTA verdicts, not the Commission’s approval, are the decisions that will answer it.
Spain’s Medicine Funding Timeline
537
Average days from EMA approval to Spanish funding decision (WAIT 2025)
8%
Share of medicines funded within EU 180-day directive window in Spain
Indication Restrictions: More than 50% of newly funded medicines in Spain carry indication restrictions, limiting initial patient access relative to approved indication scope.
Source: Farmaindustria / WAIT 2025 report (as of 2026-05-19)
Why this is relevant
Patients
Adults with primary hypercholesterolaemia or mixed dyslipidaemia now have a newly approved European option in obicetrapib, though real-world access depends on national reimbursement decisions that, in Spain alone, averaged 537 days after EMA authorisation as of the WAIT 2025 report, and more than half of newly funded medicines carried indication restrictions relative to the approved label.
Industry
The approval rehabilitates the CETP inhibitor class after high-profile Phase 3 failures by Pfizer, Roche, and Eli Lilly, and gives Menarini Group and NewAmsterdam Pharma what the companies describe as a first-in-class approval; NewAmsterdam is eligible for up to an additional €833 million in milestone payments under the partnership, though obicetrapib’s commercial potential carries substantial uncertainty given the class history.
Payers
European health-technology assessment bodies in Germany, France, Italy, and Spain will each conduct independent benefit assessments and pricing negotiations; the outcome of Germany’s G-BA early benefit assessment in particular is likely to set the reference point for whether obicetrapib commands a premium price or defaults to a comparator-based reference, with PCSK9 inhibitors evolocumab and alirocumab representing the established formulary alternatives.
Litigation
No litigation, regulatory investigation, or enforcement action has been identified in connection with the obicetrapib approval or the Menarini–NewAmsterdam partnership in the available record.
Sources: NewAmsterdam Pharma (GlobeNewswire); Menarini Group (PR Newswire); Farmaindustria (WAIT 2025)
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.
Your subscription could not be validated.
You have successfully subscribed.
